Here’s why you shouldn’t worry about Jeff Sessions meddling in marijuana: Canaccord Genuity

U.S. Attorney General Jeff Sessions Thursday rescinded Obama-era legislation that prevented the federal government from interfering with state laws around marijuana, but it will be difficult for his actions to make a real impact, Canaccord Genuity analyst Matt Bottomley says.

In a research report to clients Thursday, Bottomley addressed several reports that Jeff Sessions was would limit or terminate the “Cole Memo”, a piece of legislation issued by Deputy Attorney General James Cole that outlined strict non-intervention criteria for the feds in legal cannabis markets. The development comes just days after the country’s most populous state, California, legalized marijuana.

Many in the U.S. spoke out against the move, including Democratic Senator Ron Wyden.

“Trump promised to let states set their own marijuana policies. Now he’s breaking that promise so Jeff Sessions can pursue his extremist anti-marijuana crusade,” Wyden said in statement Thursday. “Once again the Trump administration is doubling down on protecting states’ rights only when they believe the state is right.”

Bottomley notes that medical marijuana markets already implemented in 29 states are still protected by existing legislation under the “Rohrabacher–Farr” amendment, so Sessions’ actions are limited to the recreational markets. Even then, the analyst argues, there are significant hurdles the government would need to overcome to implement federal enforcement. Bottomley say the winds are clearly at the back of legalization, despite today’s actions.

“Independent of Sessions’ plans, we believe there are still several mitigating factors at play, including: (1) over 60% of Americans support the legalization of cannabis, with bipartisan support in many US states; (2) sales from legalized markets bring in hundreds of millions of dollars in taxes annually. California’s recreational marijuana is estimated to provide the state with >$1 billion in funds once fully implemented; and (3) there are a number of bills currently in Congress that call for the protection of legalized rec markets in the US, in order eliminate crime and protect youth (including a bill introduced by Senator Corey Booker calling for the removal of marijuana from the federal Controlled Substances Act altogether),” the analyst said.

Bottomley says the overall impact of this development is that “headline risk” could spook investors in the space.

“We expect this to weigh on stocks of US cannabis companies and could hamper liquidity and new investment until further clarity is provided,” he adds.

More Cantech Cannabis

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

JUSH stock is a buy, Beacon says

With its first quarter results on deck, Beacon Securities analyst Russell Stanley thinks Jushi Holdings (Jushi Holdings Stock Quote, Chart,… [Read More]

4 hours ago

Is Curaleaf stock still a buy?

The stock has been a steady climber since last October, but ahead of earnings is Curaleaf (Curaleaf Stock Quote, Chart,… [Read More]

6 hours ago

OpenText price target cut at National Bank

Following third quarter results he describes as "in-line", National Bank Financial analyst Richard Tse has cut his price target on… [Read More]

7 hours ago

Silicon Motion stock still a buy, Roth says

Following the company's first quarter results, Roth MKM analyst Suji Desilava remains bullish on Silicon Motion Technology (Silicon Motion Technology… [Read More]

8 hours ago

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

3 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

3 days ago